Dar Zavain 4

What Happened Dar Zavain, a director of Recursion Pharmaceuticals, was granted 5,109 shares on July 1, 2026. The shares were reported at $0.00 per share (total reported cash value $0) and were issued as an award under the issuer's Outside Director Compensation Policy. This was a compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (filed the next day).
• Transaction type/code: Award/Grant (A).
• Shares received: 5,109; Price per share: $0.00; Reported value: $0.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: Shares issued pursuant to the Issuer's Outside Director Compensation Policy (F1).
• No indication of 10b5-1 plan, tax withholding, or late filing in this Form 4.

Context Awards to outside directors are common as part of board compensation and typically reflect governance/remuneration practices rather than a direct statement about the insider’s market view. Because this was a granted award with no cash exchanged, it should be interpreted primarily as compensation, not a trading signal.